Check out the story by the UW Medicine Newsroom here.
Understanding mRNA and DNA vaccines in veterinary medicine
“It was my pleasure to lecture about mRNA and DNA vaccines at the ACVIM Forum 2023” -Dr. Fuller
Read more about Dr. Fuller’s lecture at ACVIM Forum 2023 here.
Vaccine Makers Are Preparing for Bird Flu
Although most experts say bird flu is not an immediate threat to humans, efforts are underway to produce vaccines for H5N1 or another potential pandemic virus.
“RNA vaccines can be designed extremely quickly—you only need the genetic sequence of what the new variant is that’s emerging, and within weeks, [you] can have a vaccine already tested in animal models,” Fuller says.
Read more in the Scientific American
Making a Universal Flu Vaccine
How do you make a universal flu vaccine? A microbiologist explains the challenges, and how mRNA could offer a promising solution
Read Dr. Fuller’s piece in The Conversation.
Do new Covid ‘Scrabble’ variants make omicron boosters pointless? Here’s what experts say
Read what Dr. Fuller has to say on CNBC.
Researchers from NAU, Washington tackling an elusive Valley Fever vaccine
Dr. Fuller, along with NAU, have received a received a funding for a groundbreaking project that they hope will result in a safe and effective vaccine for Valley Fever.
An mRNA vaccine with a twist—it copies itself—protects against COVID-19
Fuller says a self-amplifying mRNA COVID-19 vaccine ideally would replace the two primary doses, giving it an even clearer benefit over its conventional relatives. A booster months later might still be warranted, as is encouraged now for the current mRNA vaccines. But self-amplifying mRNAs could also lead to more durable immune responses, Fuller suggests.
Read more in Science.
Dr. Fuller on Monkey Pox
Dr. Fuller in FOX13: Health experts and LGBTQI+ leaders raise awareness on monkeypox to prevent stigmatization
Dr. Fuller in the Seattle Times: Monkeypox in the COVID era: Here are the key differences between the viruses.
COVID-19: The Omicron Variant
If the omicron variant of the coronavirus is different enough from the original variant, it’s possible that existing vaccines won’t be as effective as they have been. If so, it’s likely that companies will need to update their vaccines to better fight omicron. Deborah Fuller is a microbiologist who has been studying mRNA and DNA vaccines for over two decades. Here she explains why vaccines might need to be updated and what that process would look like.
Read more in the The Conversation and the Seattle Times.
COVID Monoclonal Antibody Therapy: Everything You Need To Know
Millions of Americans are eligible to get the treatment, but not enough know they qualify — and not all three options appear to work on omicron cases.
